DME Capital Management’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$14.5M Hold
482,746
0.45% 37
2025
Q4
$15.8M Hold
482,746
0.55% 30
2025
Q3
$16.7M Hold
482,746
0.66% 23
2025
Q2
$13.5M Hold
482,746
0.58% 23
2025
Q1
$12.1M Buy
482,746
+3,383
+0.7% +$85.5K 0.61% 21
2024
Q4
$13.2M Hold
479,363
0.68% 21
2024
Q3
$13.8M Buy
479,363
+244,535
+104% +$6.66M 0.57% 26
2024
Q2
$5.82M Buy
234,828
+75,000
+47% +$2.13M 0.28% 26
2024
Q1
$5.15M Buy
+159,828
New +$5.94M 0.24% 28

Other funds holding LKFT

DME Capital Management's LKFT Position: Q1 2026 in Review

DME Capital Management held its Lakefront Biotherapeutics American Depositary Shares (LKFT) position steady in Q1 2026 at 482,746 shares worth $14.5M. The position accounts for 0.45% of the portfolio, ranked #37.

DME Capital Management first reported a position in LKFT in Q1 2024 and has held it in 9 quarters since. The position peaked at $16.7M in Q3 2025. 90 funds tracked by Wall St. Rank hold LKFT as of Q1 2026.

  • DME Capital Management held 482,746 shares of Lakefront Biotherapeutics American Depositary Shares worth $14.5M as of Q1 2026.
  • DME Capital Management left its Lakefront Biotherapeutics American Depositary Shares share count unchanged in Q1 2026.
  • Lakefront Biotherapeutics American Depositary Shares made up 0.45% of DME Capital Management's portfolio in Q1 2026, its #37 holding.
  • DME Capital Management first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q1 2024 and has held it in 9 quarters since.
  • DME Capital Management's Lakefront Biotherapeutics American Depositary Shares position peaked at $16.7M in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q1 2026.

Based on DME Capital Management's 13F filing for Q1 2026, filed 15 May 2026.